FindTrial
Sign In

A randomised, double-blind, placebo-controlled, cross-over pilot study using nabilone for symptomatic relief in patients with Huntington's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN16782845
Enrollment
Unknown
Registered
2005-09-13
Start date
2005-09-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Huntington's disease Nervous System Diseases Huntington's disease

Interventions

Nabilone or placebo for 5 weeks, 5 week washout period cross over to nabilone or placebo for 5 weeks

Sponsors

Birmingham and Solihull Mental Health Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Competent patients with a clinical diagnosis of Huntington's disease over 18

Exclusion criteria

Exclusion criteria: 1. Under 18 2. Known allergy to cannabinoids 3. Liver dysfunction 4. Personal or family history of psychosis 5. Heart disease or hypertension 6. Pregnant or lactating

Design outcomes

Primary

MeasureTime frame
Motor symptoms rated using the motor scale from the UHDRS—

Secondary

MeasureTime frame
Psychiatric symptoms rated using the behavioural assessment of the UHDRS and the NPI—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026